Atea Pharmaceuticals sees highest patent filings and grants during July in Q3 2023
Atea Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with 3 publications in Q3 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 25% filings and 0% grants. The European Patent Office(EPO), Israel(IL), Argentina(AR), and Australia(AU) patent Office are among the top ten patent offices where Atea Pharmaceuticals is filings its patents. Among the top granted patent authorities, Atea Pharmaceuticals has 60% of its grants in United States(US), 0% in European Patent Office(EPO), and 0% in Israel(IL).
Johnson & Johnson could be the strongest competitor for Atea Pharmaceuticals
In terms of grant share, Atea Pharmaceuticals stands in third position among its competitors. Johnson & Johnson and University of Texas System secured the top positions according to recent patent publication data.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Patents related to rare diseases and Covid-19 lead Atea Pharmaceuticals’s portfolio
Atea Pharmaceuticals has the highest number of patents in rare diseases followed by, Covid-19 and . For rare diseases, nearly 50% of patents were filed and 50% of patents were granted in Q3 2023.
Hepatitis c related patents lead Atea Pharmaceuticals portfolio followed by severe acute respiratory syndrome (sars), and hepacivirus infections
Atea Pharmaceuticals has highest number of patents in hepatitis c followed by severe acute respiratory syndrome (sars), hepacivirus infections, coronavirus disease 2019 (covid-19) and mobiles, hand-helds, pdas, smartphones. For hepatitis c, nearly 33% of patents were filed and 25% of patents were granted in Q3 2023.
For comprehensive analysis of Atea Pharmaceuticals’s filings and grants, buy the databook here.
Source link
#Atea #Pharmaceuticals #sees #highest #patent #filings #grants #July
